Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 June 2018 - 8:00AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
biopharmaceutical company focused on the discovery and development
of precision genetic medicine to treat rare neuromuscular diseases,
granted equity awards on June 29, 2018, that were previously
approved by the Compensation Committee of its Board of Directors
under Sarepta’s 2014 Employment Commencement Incentive Plan, as a
material inducement to employment to twenty individuals hired by
Sarepta in June 2018. The equity awards were approved in accordance
with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate,
options to purchase 84,620 shares of Sarepta's common stock. The
options have an exercise price of $132.18 per share, which is equal
to the closing price of Sarepta's common stock on June 29, 2018.
One-fourth of the shares underlying each employee’s option will
vest on the one year anniversary of his or her date of hire and
thereafter 1/48th of the shares underlying each employee’s option
will vest monthly, such that the shares underlying the option
granted to each employee will be fully vested on the fourth
anniversary of his or her date of hire, in each case, subject to
each such employee’s continued employment with Sarepta on such
vesting dates.
About Sarepta
Therapeutics
Sarepta Therapeutics is a commercial-stage
biopharmaceutical company focused on the discovery and development
of precision genetic medicine to treat rare neuromuscular diseases.
The Company is primarily focused on rapidly advancing the
development of its potentially disease-modifying Duchenne muscular
dystrophy (DMD) drug candidates. For more information, please visit
www.sarepta.com.
Internet Posting of
Information
We routinely post information that may be
important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan,
617-274-4052 iestepan@sarepta.com or W2O Group Brian Reid,
212-257-6725 breid@w2ogroup.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2024 to May 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From May 2023 to May 2024